Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"CTLA4"”.
-
CTLA4 gene polymorphisms in autoimmune hepatitis (AIH) : gene and clinical disease correlations in South African patients
Also available online. Includes bibliographical references (leaves 76-85).
-
A HIF-INDEPENDENT PROGRAM SUSTAINS TUMOR TREG FUNCTION IN OXYGEN-DEPRIVED ENVIRONMENTS
… Similarly, flow cytometry showed OX40 and CTLA4 upregulation at protein level in 3% O2, reverted to baseline by RBPJ inhibition. Suppression assay showed Treg suppressive function was accordingly dependent upon RBPJ activity in 3% O2. We validated our findings in tumor explants, a …
-
Clinical and genetical aspects of Celiac Disease
… phenotypes and HLA class II risk alleles, the CTLA4 +49 A/G polymorphism, the haplotype MH30*G:-1147*T:+49*A:CT60*G:CT61*A and the 5q31-33 locus, in CD. Th e patients were grouped according to symptoms at presentation, the age at diagnosis and gender. Th e heritability of the phenotype was …
-
Single cell and spatial analysis characterize metabolic DPEP1+ fibroblasts in PDAC
… inhibitor, Gemcitabine/Abraxane, and anti-CTLA4 can reprogram DPEP1<sup>+</sup>CAFs in the PDAC TME. Our study presents a high-resolution atlas of PDAC TME and highlights DPEP1<sup>+</sup>CAFs as a novel CAF subtype critical for PDAC progression and susceptibility to KRAS inhibitors and …
-
Parp Inhibitor Upregulates Pd-L1 Expression and Enhances Cancer-Associated Immunosuppression
… approvals for therapeutic antibodies that block CTLA4, PD-1 and PD-L1, immune checkpoints have emerged as new targets in cancer therapy. In addition, there is accumulating evidence highlighting the role of cancer-associated immunity in patient response to cytotoxic anticancer agents. Inhibitors …
-
Co-optation of B Cell Developmental States in Malignancy and Autoimmunity
… leukemia (B-ALL), cell-extrinsic signaling in CTLA4-deficient T cell-mediated follicular B cell blocks, and integrative mutational and niche-specific survival in mantle cell lymphoma (MCL). Finally, we identify how these aberrant developmental states shift or resolve upon targeted therapeutic …
-
Developing Novel Approaches to Improve Response to T Cell Based Cancer Immunotherapy
… response rate of ~50%. Treatment with anti-CTLA4 and anti –PD1 therapy, conferred response rates of up to 50%, greatly improving the overall survival of patients with advanced melanoma amongst other cancer types. Despite the encouraging outcomes, there are relatively low response rates …
-
Análise transcritômica de linfócitos T humanos tratados com anticorpos anti-CD3
… exclusivos de Tregs, tais como, CD25, FOXP3, CTLA4 e GITR. Outros genes codificavam importantes proteínas envolvidas com a função supressora das células Tregs (Ex. GZMB). Por outro lado, alguns marcadores de células Th17 também foram regulados positivamente. Citocinas de perfil Th17, tais …
-
Functional Genomic Studies of Cancer Immune Evasion Using In Vitro and In Vivo CRISPR/Cas9 Genetic Screens
… of therapeutic antibodies blocking PD1 and CTLA4, for the treatment of various cancers. Development of novel immunotherapies constitutes an extremely promising clinical prospect. However, target identification was limited in the past due to lack of high-throughput technologies. The advent of …
-
Astrocytes modulate microglial phenotype and dendritic cell-like properties
… is not due to interactions between CD80/CD86 and CTLA4. The elevated presence of Foxp3^+ T cells appears to be responsible for the lower level of T cell proliferation in the presence of isolated microglia. Finally, analysis of the supernatants from the T cell co-culture experiments reveal that …
-
The Function of LAT in T Cell Activation and Autoimmunity
… LAT deficiency reduced the expression of Foxp3, CTLA4, and CD25 in peripheral Treg cells. Interestingly, mice with LAT deleted in peripheral T cells developed a lymphoproliferative syndrome similar to that observed in LATY136F mice although the disease caused by the LATY136F mutation was more …
-
Novel approaches and pharmacological considerations in melanoma treatment
… therapies have been developed, such as anti-CTLA4 and anti-PD-1 antibodies, which enhance tumour T-cell activity, and selective BRAF (DBF; dabrafenib) and MEK (TRA; trametinib) inhibitors, that block tumour growth in patients with active BRAF mutations. Although these therapies offer …
-
Unraveling Epigenetic Mechanisms That Regulate Breast Cancer Lung Metastatic Relapse by Rewiring the Immune Microenvironment
… Traps inhibitor) and anti-LAG3+anti-CTLA4 immunotherapy regime abrogated the Brd7-KO induced lung metastasis.</p> <p>Taken together, our findings that BRD7 is a suppressor of breast cancer lung metastasis and a predictive cancer biomarker for lung metastatic relapse , could have major …
-
P4HB TARGETING HALTS TUMOR GROWTH AND RE-SENSITIZES RESISTANT MELANOMA CELLS TO DABRAFENIB AND TRAMETINIB STANDARD-OF-CARE THERAPY VIA IRE1-⍺ ACTIVATION AND AKT DOWNMODULATION
… immune checkpoints inhibitors (anti-PD1, anti-CTLA4). However, a significant proportion of BRAF-mutant patients develop secondary resistance to targeted therapies, while others exhibit even primary resistance. To either prevent or overcome resistance in BRAF-mutant melanoma patients, new …
-
Rerouting Pre-Existing Host Vaccine-Induced Immunity to wards Breast Cancer
… attempts have failed. The recent success of anti-CTLA4, PD-L1 and PD-1 antibodies targeting immune checkpoint pathways and HPV vaccines has renewed hope that patient survival can be increased through enhancing T-cell responses. We propose to test a novel approach that may bypass host immune …
-
Layer-by-Layer Nanoparticles for Cytokine Delivery
… inhibitor (CPI) therapy with anti-PD1 and anti-CTLA4, when combined with LbL-IL-12-NPs, we achieved complete responses with robust immune memory induction. The mice were able to rapidly clear rechallenges with fresh cancer cells in the i.p. space. Towards the clinical translation of …
-
TREMELIMUMAB AND DURVALUMAB COMBINATION FOR THE NON-OPERATIVE MANAGEMENT OF MICROSATELLITE INSTABILITY HIGH RESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: RESULTS OF COHORT 1 OF THE MULTICENTRE, SINGLE-ARM, MULTI-COHORT, PHASE II INFINITY STUDY
Introduzione: Nel carcinoma gastrico o della giunzione gastroesofagea (GC/GEJC), resecabile è ormai dimostrato il potente valore prognostico positivo e il potenziale valore predittivo per la mancanza di beneficio dalla combinazione di chemioterapia adiuvante/perioperatoria della presenza di alta …